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Purpose
This study was conducted in order to determine the most cost-effective strategy, in
terms of interval and age range, for liver cancer screening in the high-risk population
of Korea.
Materials and Methods
A stochastic model was used to simulate the cost-effectiveness of liver cancer screen-
ing by combined ultrasonography and alpha-fetoprotein testing when varying both
screening intervals and age ranges. The effectiveness of these screening strategies
in the high-risk population was defined as the probability of detecting preclinical liver
cancer, and cost was based on the direct cost of the screening and confirmative tests.
Optimal cost-effectiveness was determined using the incremental cost-effectiveness
ratio.
Results
Among the 36 alternative strategies, one-year or two-year interval screening for men
aged between 50 and 80 years, six-month or one-year interval screening for men
aged between 40 and 80 years, and six-month interval screening for men aged 
between 30 and 80 years were identified as non-dominated strategies. For women,
identified non-dominated strategies were: one-year interval screening between age
50 and 65 years, one-year or six-month interval screening between age 50 and 80
years, six-month interval screening between age 40 and 80 years, and six-month 
interval screening between age 30 and 80 years.
Conclusion
In Korea, a one-year screening interval for men aged 50 to 80 years would be 
marginally cost-effective. Further studies should be conducted in order to evaluate
effectiveness of liver cancer screening, and compare the cost effectiveness of differ-
ent liver cancer screening programs with a final outcome indicator such as quality-
adjusted life-years or disability-adjusted life-years.
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Introduction
Worldwide, liver cancer is the fifth most common cancer
in men (16.0 per 100,000) and the seventh in women (6.0 per
100,000), with almost 85% of cases occurring in Asia and
Africa [1]. Due to its high fatality, liver cancer is the third
most common cause of cancer death worldwide [1]. 
Although the incidence of liver cancer in Korea has declined
over the last decade, it is still the fourth most common cancer
in Korean men (37.7 per 100,000) and the seventh most 
common cancer in Korean women (10.4 per 100,000) [2]. In
addition, liver cancer is the second most common cause of
cancer death in Korea [2].
In an effort to reduce liver cancer-related mortality, 
surveillance or screening is widely practiced and generally
recommended for certain high-risk groups. Liver cancer 
occurs in populations with a well-defined set of risk factors
and has a protracted preclinical phase, meaning that timely
identification of disease can lead to appropriate treatment at
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a more curable stage; therefore, it is a suitable target for a 
surveillance program. The carcinogenic effect of chronic 
infection with hepatitis B and C viruses (HBV, HCV) in liver
cancer development has been well demonstrated by 
epidemiological and experimental evidence. However, 
evidence on efficacy of liver cancer screening (or surveil-
lance) programs has not yet been established. A number of
screening programs have been reported since the 1970s, and
tumors detected through screening were found to be smaller,
resulting in increased survival [3-6]. However, in all of these
studies, the duration of follow-up was limited, and lead-time
bias remained. A randomized controlled trial from 
conducted in Shanghai using abdominal ultrasound and
alpha-fetoprotein (AFP) every six months in 18,816 patients
aged 35-59 years with chronic hepatitis B and other risk 
factors for hepatocellular carcinomas (HCC) showed a 
reduction in mortality by 37% [7]. While these results are
promising, the confidence interval (CI) was near 1.0, 
intention-to-treat analysis was not used, assessment of 
outcome was not blinded, and generalizability to other pop-
ulations is uncertain [8]. Therefore, while screening with
AFP+ultrasonography (US) appears to detect significantly
more HCC compared with no screening, and, despite the
current recommendation to screen subjects at moderate and
high risk for HCC every six months, we do not yet know
with certainty whether screening can reduce all-cause 
mortality or HCC mortality, which modality of screening
should be used (no screening, AFP, US, or AFP+US), or how
frequently screening should be offered. It is possible that
HCC screening may be effective, but also that harm caused
by screening may outweigh any benefit [9]. The National
Cancer Institute reported that liver cancer screening would
not result in mortality reduction from HCC [8].
Despite the lack of concrete evidence, screening for liver
cancer is widely practiced and recommended for certain 
at-risk groups [10,11]. In Korea, a nationwide liver cancer
screening program was introduced in 2003 as part of the 
National Cancer Screening Program (NCSP). It was based on
the HCC Surveillance Recommendations developed by the
National Cancer Center and the Korean Association for the
Study of the Liver in 2001 [12]. The NCSP for liver cancer in
Korea provides US and AFP testing at six-month intervals to
men and women aged 40 years or older with chronic HBV
or HCV infection, liver cirrhosis, or chronic liver disease of
any cause (i.e., high-risk population). This screening strategy
is the most widely accepted and the most used in clinical
practice. However, the optimal screening interval and proper
age range for screening are still being debated.
A cancer screening program should be cost-effective and
revised according to documented epidemiological changes
of the cancer in question, and development of diagnostic
technology, especially when conducted at a national level.
However, few studies have investigated the cost-effective-
ness of liver cancer screening by consideration of various
screening intervals and age ranges. Therefore, this study was 
conducted in order to determine the most cost-effective 
strategy for men and women, in terms of interval and age
range, for liver cancer screening by combined US and AFP
testing in the high-risk population in Korea.
Materials and Methods
1. Model
To determine the most cost-effective interval and age range
for liver cancer screening, the effectiveness and the cost of
screening strategies were based on a model proposed by Lee
and Zelen [13]. The optimal screening strategy was 
determined based on the incremental cost-effectiveness ratio
(ICER), which is defined as the ratio of changes in cost and
effectiveness of one screening strategy to an alternative 
strategy.
The effectiveness of a screening strategy was measured as
the number of early-detected liver cancers found per 100,000
high-risk individuals screened. This number was derived
from the estimated probability of detecting preclinical liver
cancer, a state in which the disease has no symptoms but can
be diagnosed. The model by Lee and Zelen [13] assumes that
the natural history of a chronic disease or cancer is progres-
sive in the manner of S0→ Sp → Sc, where S0 represents Sp the 
cancer-free state, Sp the preclinical state, and Sc the clinical
state. The sensitivity of the screening method, the distribu-
tion of the mean sojourn time (MST) in the preclinical state,
and age-specific incidence rates were required for 
estimation of the probability of preclinical detection. MST is
the duration of the pre-clinical detectable phase of the cancer,
and, in the current study, it was defined as the mean time
necessary for a liver tumor to change from a screening 
detectable size to a clinically detectable size.
We assumed that both the MST and the sensitivity of the
screening method (combined US and AFP testing) were con-
stant, as assumed by the Lee and Zelen model [13]. In the
model, the time variable t refers to age, r refers to screening
round, and i refers to screening interval. Assuming that
screenings are performed at age t1≤t2 ＜…＜tn in a given pe-
riod, the probability of detecting preclinical cancer at age tr
is as follows:
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, where w(x) denotes the probability of progression from
S0 to Sp, which can be calculated by age-specific liver cancer 
incidence and an assumed distribution of MST in Sp: Q(t) is
the survival distribution of the MST in Sp at age t with tr-1≤t
＜tr, and β is the sensitivity of the modality based on the
combination of US and AFP testing.
The costs were measured as the direct cost incurred when
one individual underwent screening, which is reasonable for
low-incidence disease [13]. Costs of screening and confirma-
tive tests for false-positive outcomes were included. As 
combined US and AFP testing is used in liver cancer screen-
ing in Korea, the costs were calculated as follows:
Cost≈nKs+(1-Sp)Kd
, where n denotes the total number of screenings, Ks and
Sp represent the screening cost and specificity, respectively,
for the combination of US and AFP testing, and Kd the cost
of confirmative testing. Costs of other adverse effects from
liver cancer screening, such as discomfort from examination
or recall of patients for additional imaging, were not consid-
ered in the model. The time horizon for the study was 30 to
80 years of age. We adopted the perspective of the 
national healthcare system.
For the current study we generated 36 possible combina-
tions of screening intervals and age ranges for both men and
women, setting screening intervals of six months, one year,
or two years; an initial screening age of 30, 40, or 50 years;
and a ceiling screening age of 65, 70, 75, or 80 years (Table 1).
ICER was calculated for determination of the most cost-ef-
fective screening strategy for liver cancer among all those 
considered. Based on the calculated ICER, screening strate-
gies were classified as non-dominated, dominated, or 
extended dominated. Non-dominated strategies, in which
the  effectiveness was higher and the costs were lower than 
others, were considered the most cost-effective. A dominated
strategy was defined as generating worse effects and higher
costs than an alternative strategy. Extended dominance 
occurred when a strategy was less effective and had a higher
ICER than an alternative strategy.
2. Data and model assumptions
For estimation of age-specific liver cancer incidence rates
for the high-risk population, the high-risk population in the
NCSP database in 2008 was linked to the 2008 Korean 
National Cancer Incidence Database of the Korean Central
Cancer Registry (KCCR). In the NCSP, the National Health
Insurance (NHI) Corporation identified the high-risk group
for liver cancer screening as individuals who had been tested
or received medical care for HBV or HCV infection (ICD 10
code: B18, B18.0, B18.1, B18.2, Z22.5), chronic liver disease
(ICD 10 code: B19, K73, K73.1, K73.2. K73.8, K73.9), or liver
cirrhosis (ICD 10 code: K74, K74.1, K74.2, K74.6, K76, K70.2,
K70.3, K70.9) within the past two years, using the computer-
ized medical claims database. Incidence rates were calculated
for each age group and ranged from 30 to 34 years of age to
more than 85 years of age. The incidence of liver cancer in
the high risk group showed a gradual increase with age until
the age 80-84 years and then subsequently decreased. We 
assumed that individuals in the high-risk population aged
30 or over undergo liver cancer screening and are followed-
up until the ceiling screening age. Therefore, in the model,
high-risk individuals remained in the screening cohort and
underwent screening based on the set screening interval until
reaching the ceiling screening age (65, 70, 75, or 80 years).
Baseline assumptions regarding MST, sensitivity and
specificity, and cost of screening and confirmative tests are
shown in Table 2. A previous study conducted in Taiwan 
reported an MST of 1.57 years (95% CI, 0.94 to 4.68 years) in
cirrhotic patients and 2.66 years (95% CI, 1.68 to 6.37 years)
in non-cirrhotic patients [3]. Another study conducted in
Asia reported an MST of 3.2 years, regardless of the severity
of cirrhosis [14]. In the current study, based on the above-
mentioned study conducted in Taiwan, we assumed an MST
of 1.57 years for the high-risk population (i.e., chronic HBV
or HCV infection, liver cirrhosis, or chronic liver disease of
any cause). Sensitivity and specificity of US are known to
range from 65% to 84% and from 91% to 97%, 
respectively [6,15]. The reported sensitivity of AFP has
ranged from 39% to 69% with the standard of 20 ng/mL, and
specificity from 90% to 95% [15,16]. Sensitivity increased up
to 92% when US and AFP were combined [15]. However, due
to differences in target populations and liver cancer screen-
ing programs, direct use of these results may be difficult.
For example, most of the aforementioned studies were 
hospital-based, and, in general, the sensitivity and specificity
of these tests are lower in a community-based setting with
an asymptomatic population. A previous study reported 
sensitivity and specificity of combined US and AFP testing
in the NCSP ranging from 42% to 54% and from 94% to 96%,
respectively [17]. Thus, this study assumed a sensitivity and
specificity of combined US and AFP testing of 50% and 95%,
respectively. The unit costs of US (US$41.29), AFP (US$
10.99), and the confirmative test (magnetic resonance imag-
ing, US$311.09) were obtained from the 2009 medical insur-
ance costs published by the Health Insurance Review and
Assessment Service [18], and combined for estimation of total
costs. To assess the robustness of the proposed screening
Young Hwa Lee, Cost-Effectiveness of Liver Cancer Screening
Dr=β (1–β)r-i w(x)Q(ti–x)dx+ w(x)Q(tr–X)dx
(r=1, 2,…, n), (i=1, 2, 3,…, n)
∑ ∫ ∫[ ]
r-1
i=1
ti
ti-1
tr
tr-1
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strategies, one-way sensitivity analyses were performed by
changing the MST in the preclinical state, and the sensitivity
and specificity of combined US and AFP testing. Alternative
MSTs were 0.94, 2.66, 4.68, and 6.37 years based on the pre-
vious study [3], alternative sensitivities were 60% and 70%,
and specificity was 90%. All statistical analyses were per-
formed using MATLAB 6.1 (Mathworks Inc., Natick, MA).
Results
Tables 3 and 4 show the 36 strategies for liver cancer
screening by US and AFP in men and women in the high-
risk population, as well as the number of cases found per
100,000 high-risk individuals screened, cost per 100,000
screenings, cost per preclinical case detected, incremental
cases found, incremental cost, and ICER. They are listed in
ascending order of cost per 100,000 screenings. The most ex-
pensive strategy, with a six-month interval and an age range
of 30 to 80 years for men and women, found 5,440 and 2,212
Table 1. Strategies generated for liver cancer screening by combined ultrasonography and alpha-fetoprotein testing for the
cost-effectiveness analysis
Interval (yr) Initial age (yr) Ceiling age (yr) Strategy No. of screenings
0.5 30 65 S_0.5_3065 72
70 S_0.5_3070 82
75 S_0.5_3075 92
80 S_0.5_3080 102
40 65 S_0.5_4065 52
70 S_0.5_4070 62
75 S_0.5_4075 72
80 S_0.5_4080 82
50 65 S_0.5_5065 32
70 S_0.5_5070 42
75 S_0.5_5075 52
80 S_0.5_5080 62
1 30 65 S_1_3065 36
70 S_1_3070 41
75 S_1_3075 46
80 S_1_3080 51
40 65 S_1_4065 26
70 S_1_4070 31
75 S_1_4075 36
80 S_1_4080 41
50 65 S_1_5065 16
70 S_1_5070 21
75 S_1_5075 26
80 S_1_5080 31
2 30 65 S_2_3065 18
70 S_2_3070 21
75 S_2_3075 23
80 S_2_3080 26
40 65 S_2_4065 13
70 S_2_4070 16
75 S_2_4075 18
80 S_2_4080 21
50 65 S_2_5065 8
70 S_2_5070 11
75 S_2_5075 13
80 S_2_5080 16
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preclinical cases per 100,000 high-risk individuals screened,
respectively. The least expensive screening plan, consisting
of a screening interval of two years for men and women with
an age range of 50 to 65 years, detected 915 and 338 preclin-
ical cases per 100,000 high-risk individuals screened, respec-
tively.
Among the 36 alternative strategies for men, five
(S_2_5080, S_1_5080, S_1_4080, S_0.5_4080, and S_0.5_3080)
were identified as non-dominated strategies, and others were
eliminated by either simple or extended dominance. The
least expensive strategy was compared to a plan in which no
screening was performed. The two-year or one-year interval
non-dominated screening plans for the age range of 50 to 80
years had an ICER of US$40,802, US$71,020 per case 
detected, respectively. However, two-year non-dominated
screening plans showed fewer cases per 100,000 screened,
which was less than 40% of cases from the most expensive
strategy (S_0.5_3080). Compared to a two-year interval plan
for the 50-80 year age group, extending one-year screening
for the age range of 50 to 80 (S_1_5080) was the next 
non-dominated strategy with an ICER of US$71,020 per one
case found. The non-dominated screening plans above
S_1_4080, such as S_0.5_4080 and S_0.5_3080 were not 
relatively cost-effective because the costs of these strategies
were five times higher than the least expensive strategy
(Table 3).
For women, identified non-dominated strategies were as
follows: S_1_5065, S_1_5080, S_0.5_5080, S_0.5_4080, and
S_0.5_3080 (Table 4). However, the ICERs of non-dominated
strategies for women were at least two times higher than
those for men. Compared to a one-year interval for the age
range of 50 to 65 years (S_1_5065), extending one-year screen-
ing to age group 50-80 resulted in an increase in ICER from
US$87,049 to US$153,976 (Table 4).
Fig. 1 illustrates our expansion path results consisting of
the most cost-effective screening strategies. The expansion
path graph, which plots the expected number of detected
cases against the costs of each screening strategy, was 
illustrated based on the ICER shown in Tables 3 and 4. The
graph representing the ICER shows a slow increase up to the
S_1_4080 strategy for men and S_1_5080 strategy for women,
but a steep increase at the S_0.5_4080 strategy for men and
S_0.5_5080 strategy for women. In other words, the graph 
visually demonstrates that strategies above S_1_4080 for men
and S1_5080 for women required large additional costs in
order to achieve increasing effectiveness. Considering the
ICER and the relative detection probability in the preclinical
stage, the S_1_5080 and S_1_4080 strategies were chosen as
the most cost-effective strategies for Korean men. For
a)Combined ultrasonography and alpha-fetoprotein (AFP) testing, b)Ultrasonography (US$41.29)+AFP (US$10.99)=52.28, c)Mag-
netic resonance imaging=US$311.09.
Table 2. Baseline assumptions and ranges tested in the sensitivity analysis
Parameters Baseline model Sensitivity analysis Reference
Mean sojourn time (yr) 1.57 0.94-4.68 7
(0.94, 2, 2.66, 4.68)
Screening testa)
Sensitivity (%) 50 60, 70 16
Specificity (%) 95 90 16
Unit cost (US$)
Screening testa) 52.28b) 17
Confirmative test 311.09c) 17
Co
st
s 
(U
S$
)
S2_5080
S1_5080
S1_5065
S0.5_3080 S0.5_3080
S0.5_4080 S0.5_4080
S0.5_5080
S1_5080
S1_4080
S2_5065 S2_5080S2_5070 S2_5075 S1_5065
S0.5_3080S0.5_4080S0.5_5080S1_3080
S1_5075S2_4080 S1_5070 S1_5080 S1_4080
600,000,000
500,000,000
400,000,000
300,000,000
200,000,000
100,000,000
0 3,000 4,000 5,000 6,0002,0001,000
Effectiveness (cases found per 100,000)
Women Men
Fig. 1. Expansion path graph of the most cost-effective
strategies for liver cancer screening by combined 
ultrasonography and alpha-fetoprotein in Korean men
and women.
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women, the ICER showed a steeper increase than for men,
more than two times higher.
Sensitivity analyses of the identified cost-effective strate-
gies for men and women were performed based on the 
different parameter settings (Table 5). The non-dominated
strategies selected from each model for sensitivity showed
consistency with those from the baseline model (data not
shown). According to the various values of sensitivity 
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ICER, incremental cost-effectiveness ratio; E. dominated, extended dominated. a)Cases found in the preclinical state per 100,000
screenings=detection probability×100,000, b)Incremental cases found in the preclinical state compared with the next least 
expensive, non-dominated strategy, c)Incremental cost compared with the next least expensive, non-dominated strategy, 
d)Incremental cost/incremental cases found in preclinical state.
Table 3. Cost effectiveness of strategies for liver cancer screening by combined ultrasonography and alpha-fetoprotein
testing in Korean men
Cases Cost per
Cost/Case
Strategy
founda) 100,000
detected
Incremental Incremental
ICERd)
Category of
per 100,000 screenings
(US$)
cases foundb) costc) dominance
screened (US$)
S2_5065 914.7 43,379,435 47,425 914.7 43,379,435 47,425 E. dominated
S2_5070 1,319.9 59,063,435 44,748 1,319.9 59,063,435 44,748 E. dominated
S2_4065 1,264.3 69,519,435 54,987 - - - Dominated
S2_5075 1,633.2 69,519,435 42,566 1,633.2 69,519,435 42,566 E. dominated
S2_4070 1,669.5 85,203,435 51,035 1,669.5 85,203,435 51,035 E. dominated
S2_5080 2,088.2 85,203,435 40,802 2,088.2 85,203,435 40,802 -
S1_5065 1,511.9 85,203,435 56,355 - - - Dominated
S2_3065 1,464.7 95,659,435 65,310 - - Dominated
S2_4075 1,982.8 95,659,435 48,245 - - - Dominated
S2_3070 1,869.9 111,343,435 59,545 - - - Dominated
S2_4080 2,437.7 111,343,435 45,676 349.5 26,140,000 74,793 E. dominated
S1_5070 2,015.8 111,343,435 55,235 - - - Dominated
S2_3075 2,183.2 121,799,435 55,789 - - - Dominated
S2_3080 2,638.2 137,483,435 52,113 550.0 52,280,000 95,055 E. dominated
S1_4065 2,038.3 137,483,435 67,450 - - - Dominated
S1_5075 2,615.6 137,483,435 52,563 - - - Dominated
S1_4070 2,542.3 163,623,435 64,360 - - - Dominated
S1_5080 3,192.4 163,623,435 51,254 1,104.2 78,420,000 71,020 -
S0.5_5065 2,035.8 168,851,435 82,941 - - - Dominated
S1_3065 2,345.7 189,763,435 80,898 - - - Dominated
S1_4075 3,142.0 189,763,435 60,396 - - - Dominated
S1_3070 2,849.6 215,903,435 75,766 - - - Dominated
S1_4080 3,718.9 215,903,435 58,056 526.5 52,280,000 99,297 -
S0.5_5070 2,707.7 221,131,435 81,668 - - - Dominated
S1_3075 3,449.4 242,043,435 70,170 - - - Dominated
S1_3080 4,026.2 268,183,435 66,610 307.3 52,280,000 170,127 E. dominated
S0.5_4065 2,740.4 273,411,435 99,771 - - - Dominated
S0.5_5075 3,512.6 273,411,435 77,837 - - - Dominated
S0.5_4070 3,412.2 325,691,435 95,449 - - - Dominated
S0.5_5080 4,284.0 325,691,435 76,025 565.1 109,788,000 194,281 E. dominated
S0.5_3065 3,151.7 377,971,435 119,926 - - - Dominated
S0.5_4075 4,217.2 377,971,435 89,626 - - - Dominated
S0.5_3070 3,823.5 430,251,435 112,528 - - Dominated
S0.5_4080 4,988.5 430,251,435 86,249 1,269.6 214,348,000 168,831 -
S0.5_3075 4,628.5 482,531,435 104,252 - - - Dominated
S0.5_3080 5,399.8 534,811,435 99,043 411.3 104,560,000 254,218 -
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ICER, incremental cost-effectiveness ratio; E. dominated, extended dominated. a)Cases found in the preclinical state per 100,000
screenings=detection probability×100,000, b)Incremental cases found in the preclinical state compared with the next least 
expensive, non-dominated strategy, c)Incremental cost compared with the next least expensive, non-dominated strategy, 
d)Incremental cost/incremental cases found in preclinical state.
Table 4. Cost effectiveness strategies for liver cancer screening by combined ultrasonography and alpha-fetoprotein testing
in Korean women
Cases Cost per
Cost/Case
Strategy
founda) 100,000
detected
Incremental Incremental
ICERd)
Category of
per 100,000 screenings
(US$)
cases foundb) costc) dominance
screened (US$)
S2_5065 337.5 43,379,435 128,532 337.5 43,379,435 128,532 E. dominated
S2_5070 539.6 59,063,435 109,458 539.6 59,063,435 109,458 E. dominated
S2_4065 407.3 69,519,435 170,684 - - - Dominated
S2_5075 694.6 69,519,435 100,086 694.6 69,519,435 100,086 E. dominated
S2_4070 565.8 85,203,435 150,589 - - - Dominated
S2_5080 609.4 85,203,435 139,815 - - - Dominated
S1_5065 978.8 85,203,435 87,049 978.8 85,203,435 87,049 -
S2_3065 441.6 95,659,435 216,620 - - - Dominated
S2_4075 764.5 95,659,435 125,127 - - - Dominated
S2_3070 643.7 111,343,435 172,974 - - - Dominated
S2_4080 821.7 111,343,435 135,504 - - - Dominated
S1_5070 1,048.7 111,343,435 106,173 69.9 26,140,000 373,963 E. dominated
S2_3075 798.7 121,799,435 152,497 - - - Dominated
S2_3080 672.8 137,483,435 204,345 - - - Dominated
S1_4065 1,082.9 137,483,435 126,959 104.1 52,280,000 502,209 E. dominated
S1_5075 1,118.5 137,483,435 122,918 35.6 52,280,000 374,230 E. dominated
S1_4070 928.7 163,623,435 176,185 - - - Dominated
S1_5080 1,488.1 163,623,435 109,955 509.3 78,420,000 153,976 -
S0.5_5065 762.6 168,851,435 221,415 - - Dominated
S1_3065 724.9 189,763,435 261,779 - - - Dominated
S1_4075 1,225.5 189,763,435 154,846 - - - Dominated
S1_3070 980.8 215,903,435 220,130 - - - Dominated
S1_4080 1,595.1 215,903,435 135,354 107.0 52,280,000 488,598 E. dominated
S0.5_5070 1,104.7 221,131,435 200,173 - - - Dominated
S1_3075 1,277.7 242,043,435 189,437 - - - Dominated
S1_3080 1,647.3 268,183,435 162,802 159.2 104,560,000 656,784 E. dominated
S0.5_4065 905.8 273,411,435 301,845 - - - Dominated
S0.5_5075 1,502.9 273,411,435 181,923 - - - Dominated
S0.5_4070 1,248.0 325,691,435 260,971 - - - Dominated
S0.5_5080 1,999.0 325,691,435 162,927 510.9 162,068,000 317,221 -
S0.5_3065 975.6 377,971,435 387,425 - - - Dominated
S0.5_4075 1,646.1 377,971,435 229,616 - - - Dominated
S0.5_3070 1,317.7 430,251,435 326,517 - - - Dominated
S0.5_4080 2,142.2 430,251,435 200,846 143.2 104,560,000 730,168 -
S0.5_3075 1,715.9 482,531,435 281,212 - - - Dominated
S0.5_3080 2,212.0 534,811,435 241,777 69.8 104,560,000 1,497,994 -
Young Hwa Lee, Cost-Effectiveness of Liver Cancer Screening
parameters, relative ratio of cases to base-line model ranged
from 100% to 124% of the baseline model for men and
women, except the mean sojourn time. Cases found per
100,000 screened for the different values of mean sojourn
time varied from 73% to 191% of the baseline model.
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Discussion
There is a general consensus among researchers and 
clinicians that liver cancer screening in high-risk groups has
the potential to significantly reduce mortality [3,7]. 
However, due to a lack of information on its cost-effective-
ness, there are limitations to introduction of liver cancer
screening as a nationwide program. Optimal screening inter-
val and the initial and ceiling screening age are the two major
issues in liver cancer screening, as these factors are directly
related to the detection rate of preclinical liver cancer, as well
as the total cost of a program.
The optimal screening interval should be determined by
tumor growth rate. An interval that is too long would allow
tumors to grow to an extent that would preclude curative
treatment. The mean tumor volume doubling time was 
estimated as 117-127 days (95% confidence interval, 80 to 203
days) [14,19]. Based on these tumor doubling times, a screen-
ing interval of 4-12 months has been suggested [14]. 
However, a retrospective study conducted on cirrhotic 
patients reported no differencein survival in patients
screened at six- or 12-month intervals [20]. In addition, one
study used a mathematical analysis for the tumor growth
rate among HBV carriers, and showed that screening at 
10-month or one-year intervals was the most cost-effective
[21]. However, in studies of high-risk populations for liver
cancer, screening at six-month intervals resulted in improved
survival compared to one-year intervals [20,22]. Although
most experts use a six-month interval, there are no clear data
to suggest that it is the most-cost effective screening interval.
In the current study, we explored three screening intervals:
six months, one year, or two years, and the results showed
that a one-year interval was the most cost-effective for both
men and women.
Cost-effectiveness can be improved if screening is limited
to well-defined groups of patients. In the case of liver cancer,
chronic HBV and HCV infection are recognized as major risk
factors for liver cancer. Cirrhosis is also a risk factor for liver
cancer, irrespective of etiology, as is increasing age and male
gender. However, only a limited number of studies have 
addressed the question of whether screening for liver cancer
should or could be restricted to individuals within a certain
age range. The initial screening age should be determined by
the relationship between age and the incidence rate of liver
cancer. In Korea, due to the high prevalence of HBV infection
and related liver problems, the government introduced an
HBV vaccination program in 1983; the vaccine was offered
to government employees, soldiers, and students on a 
voluntary basis. In 1995, a national HBV vaccination 
program for infants and children was launched, followed by
a 2002 national vaccination program directed at HBV-in-
fected mothers for prevention of vertical transmission to their
newborns. Thereafter, hepatitis B surface antigen seroposi-
tivity among members of the Korean population under 20
years of age showed a dramatic decrease to 2% [23]. Cur-
rently, most members of the Korean population under 20
years of age were born after introduction of the HBV vacci-
nation program. Compared to this population, Koreans over
30 years of age have a higher prevalence of HBV infection.
In the current study, we estimated the age-specific liver can-
cer incidence rates for the high-risk population between ages
30 and 80 years. Based on these incidence data, our results
showed that the most cost-effective age range for liver cancer
screening was from 50 to 80 for men and women.
The purpose of our study was to determine the most cost-
effective screening interval and age range based on the 
epidemiological characteristics of liver cancer in Korean men
and women. In Korea, the entire population is enrolled in the
mandatory NHI program, and liver cancer screening 
sponsored by the NHI is free of charge for most beneficiaries.
Therefore, we performed the analysis from the perspective
of the national healthcare system as we were primarily 
concerned with determining direct payments from the gov-
ernment. In this study, we did not measure indirect costs or
lost productivity associated with liver cancer.
The effectiveness of a cancer screening program is assessed
by decreases in cancer mortality rates; therefore, life-year
gained (LYG), quality-adjusted life-years (QALY), or disabil-
ity-adjusted life-years (DALY) are often used as the final 
endpoint for evaluation of screening strategies [24]. 
Although there is no consensus on a cost-effectiveness
threshold below which an intervention would be considered
unequivocally cost effective, a value of US$50,000/QALY is
often cited as a benchmark [24]. On the whole, liver cancer
screening in Korea might not be as cost-effective based on
the threshold of US$50,000. However, we should consider
that the cost effectiveness threshold is often referred to as so-
ciety’s willingness topay for an additional unit of health gain
(i.e., cancer detection). Thus, in the current study, interven-
tions were classified based on the level of cost-effectiveness
by convention, as described in the literature [25]: cost saving
(an intervention generates a better health outcome and costs
less than the comparison intervention) or cost neutral
(ICER=0); very cost-effective (0＜ICER≤US$25,000); cost-ef-
fective (US$25,000＜ICER≤US$50,000); marginally cost-ef-
fective (US$50,000＜ICER≤US$100,000); or not cost-effective
(US$100,000). In the current study, considering the high bur-
den of liver cancer in Korea, we set a threshold of
ICER≤US$100,000 (marginally cost-effective). In this regard,
the relatively cost-effective strategies were identified in the
analysis: 1) two-year interval for men in the age range 50 to
80 years (ICER, US$40,802); 2) one-year interval for men in
the age range 50 to 80 years (ICER, US$71,020); 3) one-year
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screening interval for men in the age range 40 to 80 years
(ICER, US $99,297); 4) one-year interval for women in the age
range 50 to 65 years (ICER, US$87,049).
Our study has several limitations. One was the hypothesis
that the rate of participation in liver cancer screening would
be the same for all age ranges. In reality, different screening
intervals and age ranges could affect the participation rate
and in turn the cost-effectiveness analysis, depending on the
strategies chosen. Conduct of afuture study will be needed
in order to reflect the participation rate in the model.
In addition, we utilized the Korean National Cancer 
Incidence Database and NCSP database for estimation of the
age-specific incidence rates of liver cancer in the high risk
group. Because the voluntarily participating hospitals in
KCCR could not cover all new cases in the entire country, the
incidence rates could be underestimated. In addition, the
high risk group for liver cancer identified from the NCSP
database could not cover all high risk populations, because
in the NCSP, individuals who had been tested or received
medical care for HBV or HCV infection, chronic liver disease,
or liver cirrhosis within the past two years were selected as
the high risk group for liver cancer. However, underestima-
tion of incidence itself does not influence the estimate of the
number of examinations because the age-specific incidence
rates are not unevenly underestimated over all ages.
In addition, we do not have data on the MST for liver 
cancer in Korea. As a result, the analysis had to be performed
using reference data from Taiwan [3], which were assumed
to be similar to Korean data. In the analysis, we did not 
distinguish between screening strategies for cirrhotic and 
non-cirrhotic patients, as we could not estimate liver cancer
incidence rates for these groups separately. In addition, in
the screening program at the national level, adoption of 
different screening strategies according to an individual’s 
underlying condition (i.e., cirrhotic or non-cirrhotic) is very
difficult. The NCSP for liver cancer in Korea provides the
same screening services to both cirrhotic and non-cirrhotic
patients: consequently, we simply adopted a conservative
MST value of 1.57 years in the baseline model for determi-
nation of the most cost-effective strategy for liver cancer
screening, in terms of interval and age range for the defined
high-risk population in Korea. We also performed sensitivity
analyses by changing the MST in the preclinical state.
Finally, to identify the most cost-effective screening inter-
val and target age range, we considered cases detected at the
preclinical state as potential surrogate outcomes in screening
strategies instead of LYG or QALY. The cost-effectiveness
model using mortality reduction as an indicator of effective-
ness (LYG, QALY, and DALY) mostly demands various 
parameters, such as progressive transition probabilities from
state to state, fatality rate for each state, and medical costs 
related to treatment methods, such as transplantation,
transarterial chemoembolization, radio frequency ablation,
and so on. However, in order to obtain adequate statistical
estimates, conduct of long follow-up clinical trials with a 
sufficiently large number of subjects would be required. As
we were not able to obtain a sufficient amount of the data
mentioned above on liver cancer in Korea, using the number
of preclinical cases detected might be the best alternative for
measuring effectiveness in this study. In addition, evidence
for decreased liver cancer mortality following early detection
was reported in a clinical trial of early detection [7]. 
However, conduct of further studies might be needed in
order to evaluate the effectiveness of liver cancer screening
with a final outcome indicator such as LYS, QALY, or DALY.
Despite these limitations, to the best of our knowledge, this
is the first study to use a probability model for identification
of cost-effective liver cancer screening strategies. The analy-
sis used to simulate the estimated cost of liver cancer screen-
ing was based on fewer assumptions and provided more
robust results when compared to the existing cost-effective-
ness analysis method.
Conclusion
Findings of the current study demonstrate that a one-year
screening interval for both men and women aged 50 to 80
years would be cost-effective. However, based on the 
relatively high incidence of liver cancer in Korean men, a
one-year interval in the high-risk population aged 40 years
or older is also acceptable. Therefore, we cautiously suggest
that the initial screening age be changed from 40 to 50 years
for women; a screening interval of one year would be 
considered a cost-effective alternative for men and women.
However, due to the lack of concrete evidence regarding
liver cancer screening, further studies should be conducted
in order to examine the effectiveness of liver cancer screening
in reduction of mortality. Also, additional research might be
needed for comparison of the cost effectiveness of different
liver cancer screening programs with a final outcome 
indicator such as QALY or DALY.
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